Partnering With Us
We believe that through collaboration, we can advance drug discovery and development to make a real difference in the lives of patients. With our own investments into proprietary technology platforms forming the basis for highly cost effective R&D in a joint ecosystem, we focus on data-driven precision medicine and early disease relevance to drive up probabilities of success (PoS). Within our pipeline co-creation model, our partners benefit from flexible access to our state-of-the art technology platforms and experienced researchers and scientists to generate R&D returns and therapeutics from their variable costs forming a shared R&D economy.
Always with the end goal in mind, we form result-driven partnerships to co-create assets and intellectual property by leveraging Evotec assets, targets, and propriety technology platforms together with our partners' for co-development or new co-creation. With our state-of-the art solutions, built always with the highest quality standards and on top of our successful track record, we bring a capital-efficient model to drug discovery and development for medicines that matter.
>500
Partners across shared R&D economy working in parallel on our platform
>50
Compounds that have been approved for clinical trials
~10%
Year over year growth in customer base
>90%
Repeat business
~50%
More cost efficient
~30%
Time saved to IND
>500
Partners across shared R&D economy working in parallel on our platform
>50
Compounds that have been approved for clinical trials
~10%
Year over year growth in customer base
>90%
Repeat business
~50%
More cost efficient
~30%
Time saved to IND
